Bleomycin and IL-1β–mediated pulmonary fibrosis is IL-17A dependent
Open accessThe DOI matches its Crossref record; 82 of the 84 references it cites were found in a registry or an index.
Abstract
Idiopathic pulmonary fibrosis (IPF) is a destructive inflammatory disease with limited therapeutic options. To better understand the inflammatory responses that precede and concur with collagen deposition, we used three models of pulmonary fibrosis and identify a critical mechanistic role for IL-17A. After exposure to bleomycin (BLM), but not Schistosoma mansoni eggs, IL-17A produced by CD4+ and γδ+ T cells induced significant neutrophilia and pulmonary fibrosis. Studies conducted with C57BL/6 il17a−/− mice confirmed an essential role for IL-17A. Mechanistically, using ifnγ−/−, il10−/−, il10−/−il12p40−/−, and il10−/−il17a−/− mice and TGF-β blockade, we demonstrate that IL-17A–driven fibrosis is suppressed by IL-10 and facilitated by IFN-γ and IL-12/23p40. BLM-induced IL-17A production was also TGF-β dependent, and recombinant IL-17A–mediated fibrosis required TGF-β, suggesting cooperative roles for IL-17A and TGF-β in the development of fibrosis. Finally, we show that fibrosis induced by IL-1β, which mimics BLM-induced fibrosis, is also highly dependent on IL-17A. IL-17A and IL-1β were also increased in the bronchoalveolar lavage fluid of patients with IPF. Together, these studies identify a critical role for IL-17A in fibrosis, illustrating the potential utility of targeting IL-17A in the treatment of drug and inflammation-induced fibrosis.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures









Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“IL-17A increases and stabilizes TGF-βRII expression on fibroblasts, thereby enhancing their sensitivity to TGF-β120”
From Fibrosis: from mechanisms to medicines (2020) · cites this paper as [120]
In the citing paper
“the functions of IL-17 include stimulation of ECM production, collagen disposition, and mediation of TGF-β signaling (144).”
From The Role of Immune and Inflammatory Cells in Idiopathic Pulmonary Fibrosis (2018) · cites this paper as [144]
In the citing paper
“murine studies in which administration of IL-17A is sufficient to induce collagen accumulation and fibrotic lesions (144, 145)”
From The Role of Immune and Inflammatory Cells in Idiopathic Pulmonary Fibrosis (2018) · cites this paper as [144]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Bettelli, E., Carrier, Y., Gao, W., Korn, T., Strom, T. B., Oukka, M., Weiner, H. L., & Kuchroo, V. K. (2006) · Nature · doi:10.1038/nature04753 · Cited by 6,992 · cited 6×
“More recently, studies have also suggested important inflammatory activities for TGF, with TGF providing an integral differentiation signal for the develop ment of proinflammatory IL17A–secreting cells (Bettelli et al., 2006; Veldhoen et al., 2006).”
BackgroundResultInfluentialCellular and molecular mechanisms of fibrosis
Wynn, T. (2008) · The Journal of Pathology · doi:10.1002/path.2277 · Cited by 4,495
Self-citationIL-23 drives a pathogenic T cell population that induces autoimmune inflammation
Langrish, C. L., Chen, Y., Blumenschein, W. M., Mattson, J., Basham, B., Sedgwick, J. D., McClanahan, T., Kastelein, R. A., & Cua, D. J. (2005) · The Journal of Experimental Medicine · doi:10.1084/jem.20041257 · Cited by 4,099 · cited 5×
“These observations also suggest that IL10 inhibits the development of BLMinduced fibrosis by targeting the proinflammatory IL23–IL17A pathway rather than the IL12–IFN axis.”
BackgroundInfluentialVeldhoen, M., Hocking, R. J., Atkins, C. J., Locksley, R. M., & Stockinger, B. (2006) · Immunity · doi:10.1016/j.immuni.2006.01.001 · Cited by 3,605 · cited 3×
“However, recent studies demonstrated that TGF is also critically involved in the development of IL17A–producing lymphocytes (Bettelli et al., 2006; Veldhoen et al., 2006), which regulate the development of a variety of inflammatory and autoimmune diseases (Tesmer et al., 2008).”
BackgroundSutton, C. E., Lalor, S. J., Sweeney, C. M., Brereton, C. F., Lavelle, E. C., & Mills, K. H. G. (2009) · Immunity · doi:10.1016/j.immuni.2009.08.001 · Cited by 1,553 · cited 3×
“Similarly, IL1 can stimulate IL17A production (Sutton et al., 2009), and IL1 is a critical mediator of pulmonary fibrosis (Gasse et al., 2007).”
BackgroundMcGeachy, M. J., Bak-Jensen, K. S., Chen, Y., Tato, C. M., Blumenschein, W., McClanahan, T., & Cua, D. J. (2007) · Nature Immunology · doi:10.1038/ni1539 · Cited by 1,520 · cited 3×
“Similar to previ ous studies (McGeachy et al., 2007; Stumhofer et al., 2007), IL10 was often coexpressed with IL17A and RoRt, sug gesting that Th17 cells may develop into IL10–secreting cells to limit Th17 effector function.”
ResultInduction and effector functions of TH17 cells
Bettelli, E., Korn, T., Oukka, M., & Kuchroo, V. K. (2008) · Nature · doi:10.1038/nature07036 · Cited by 1,216 · cited 2×
“, 2006), which regulate the pathogenesis of a variety of autoimmune and inflammatory diseases (Bettelli et al., 2008).”
BackgroundTesmer, L. A., Lundy, S. K., Sarkar, S., & Fox, D. A. (2008) · Immunological Reviews · doi:10.1111/j.1600-065x.2008.00628.x · Cited by 1,102
Nakae, S., Komiyama, Y., Nambu, A., Sudo, K., Iwase, M., Homma, I., Sekikawa, K., Asano, M., & Iwakura, Y. (2002) · Immunity · doi:10.1016/s1074-7613(02)00391-6 · Cited by 1,052 · cited 1×
“However, IL17A has been implicated in IL13– associated airway hyperreactivity (Nakae et al., 2002).”
BackgroundOrtiz, L. A., DuTreil, M., Fattman, C., Pandey, A. C., Torres, G., Go, K., & Phinney, D. G. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0704421104 · Cited by 1,019 · cited 1×
“These observations are consistent with studies that suggested IL10 could regulate the magnitude and effec tor function of Th17 responses (Fitzgerald et al., 2007; McGeachy et al., 2007; Chang et al., 2008).”
Result
Cited by
Items 601–700 of 751
Immunological mechanisms and therapeutic approaches in pulmonary fibrosis
Nell, L. M., Hendriks, R. W., Wijsenbeek, M. S., Corneth, O. B. J., & Koudstaal, T. (2026) · European Respiratory Review · doi:10.1183/16000617.0227-2025 · Cited by 5
“Th17-derived IL-17A reinforces fibrosis by enhancing TGF-β signalling in fibroblasts and inducing IL-6 production by fibroblasts and other resident cells [17, 126, 127].”
Karaselek, M. A., Duran, T., Küççüktürk, S., Vatansev, H., & Oltulu, P. (2024) · Apmis · doi:10.1111/apm.13445 · Cited by 4
VISTA Deficiency Exacerbates the Development of Pulmonary Fibrosis by Promoting Th17 Differentiation
Xie, H., Zhong, X., Chen, J., Wang, S., Huang, Y., & Yang, N. (2024) · Journal of Inflammation Research · doi:10.2147/jir.s458651 · Cited by 4
“6,9,10 Additionally, research has demonstrated that IL-17A enhances collagen synthesis and secretion, promotes epithelial–mesenchymal transition, and suppresses epithelial cell autophagy, all contributing to the exacerbation of PF. 11 Despite these findings, the molecules and specific mechanisms…”
BackgroundLopes, G. A. O., Lima, B. H. F., de Freitas, C. S., Peixoto, A. C., Soriani, F. M., Cassali, G. D., Ryffel, B., Teixeira, M. M., Machado, F. S., & Russo, R. C. (2024) · Immunity Inflammation and Disease · doi:10.1002/iid3.70042 · Cited by 3
“35,40,42,67,68 IL ‐ 1 β , 69,70 IL ‐ 6, 71 and TGF ‐ β 1 72 are potent inducers of fibrosis as they not only affect leukocytes but also activate resident cells such as fibroblasts and myofibroblasts, leading to proliferation, differentiation, and collagen production.”
Prevalence and clinical features of interstitial lung disease in patients with psoriasis
Kanaji, N., Misaki, N., Murota, M., Iwata, M., Ishikawa, R., Yamamura, K., Tanaka, H., Yokota, N., Fujimoto, S., Yajima, T., et al. (2024) · BMC Pulmonary Medicine · doi:10.1186/s12890-024-03450-7 · Cited by 4
Genetic underpinning of idiopathic pulmonary fibrosis: the role of mucin
Kiaei, S. Z. F., & Schwartz, D. A. (2025) · Expert Review of Respiratory Medicine · doi:10.1080/17476348.2025.2464035 · Cited by 6
“Studies have demonstrated that IL-17A interacts with IL-1β to enhance MUC5B expression by activating NF-κB, which then binds to the promoter region of the MUC5B gene [140–143].”
Bernardinello, N., Pezzuto, F., D’Sa, L., Vedovelli, L., Giraudo, C., Chelu, A., Chellis, C. D., Lunardi, F., Fortarezza, F., Boscaro, F., et al. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1514439 · Cited by 3
Up‐regulated integrinα4β1 on systemic lymphocytes and serum IL ‐17 A in interstitial pneumonia
Taooka, Y., Ohe, M., Tada, M., Sutani, A., & Isobe, T. (2015) · The Clinical Respiratory Journal · doi:10.1111/crj.12277 · Cited by 4
The immunopathogenesis of fibrosis
Ihnatovich, T., & Zafranskaya, M. M. (2019) · Immunopathology Allergology Infectology · doi:10.14427/jipai.2019.1.6 · Cited by 3
“Показано, что блокада IL-22, продуцируемого Тh17, γδТ-, В-, NK-клетками и макрофагами, обладающего иммуносупрессивным действием и усиливающего выработку гранулоцитарного колониестимулирующего фактора (G-CSF), приводит к усилению депонирования коллагена при экспериментальном легочном фиброзе.”
Murray, L. A., Homer, R., Gulati, M., & Herzog, E. L. (2014) · Elsevier eBooks · doi:10.1016/b978-0-12-386456-7.05307-7 · Cited by 4
Development of Adaptive Immunity and Its Role in Lung Remodeling
Esnault, S. J., & Jarjour, N. N. (2023) · Advances in experimental medicine and biology · doi:10.1007/978-3-031-32259-4_14 · Cited by 4
Kinjo, T., Tomaru, K., Haines, D. C., & Klinman, D. M. (2012) · Respiratory Research · doi:10.1186/1465-9921-13-47 · Cited by 3
“Effect of CpG ODN on IL-10, IL-17 and TGF-β expression Recent reports show that IL-17A plays a critical role in BLM-induced lung injury, and that it interacts synergistically with TGF-β to amplify the development of fibrosis [16-18].”
BackgroundInfluentialEl-Hady, M. H. A., Abaza, B. E., Fathy, G. M., Badawey, M. S., Nada, S. M., El-Shafey, M. A., & Hesham, R. (2013) · Cited by 3
Tissue Remodeling and Repair During Type 2 Inflammation
Chan, A. J., Jang, J. C., & Nair, M. G. (2015) · Springer eBooks · doi:10.1007/978-1-4939-2911-5_7 · Cited by 3
Novel Strategies to Prevent, Mitigate or Reverse Radiation Injury and Fibrosis
Montay‐Gruel, P., Boivin, G., & Vozenin, M. (2016) · Springer eBooks · doi:10.1007/978-3-319-45594-5_4 · Cited by 2
Role of IL-17 cytokines in tubal fibrosis and infertility due to salpingitis
Zhao, J., & Liu, L. (2025) · Molecular Biology Reports · doi:10.1007/s11033-025-11199-3 · Cited by 2
“Studies have shown that sustained activation of the NLRP3 inflammasome is closely linked to increased chemokine expression, recruit - ment of neutrophils and macrophages, and continuous production of IL-17Aand TNF-α [77].”
Nyaupane, U., Johannson, K. A., Kelly, M. M., & Kai, F. (2025) · Experimental Lung Research · doi:10.1080/01902148.2025.2582970 · Cited by 1
Nishimura, H., Kawano, H., Sato, S., Imakura, T., Yamashita, Y., Murakami, K., Haji, K., Bando, H., Naito, N., Kagawa, K., et al. (2025) · The Journal of Medical Investigation · doi:10.2152/jmi.72.298 · Cited by 2
Immunomodulatory biomaterials for treating chronic inflammation at mucosal sites
Babb, L. M., Kulapurathazhe, M. J., & Collier, J. H. (2025) · npj Biomedical Innovations. · doi:10.1038/s44385-025-00052-8 · Cited by 4
“In the second stage, as the in fl ammatory cytokine milieu begins to subside, a reparative phenotype is commonly induced with the recruitment of regulatory T (Treg) cells, T H 2 cells, and M2-like macrophages responsible for producing pro-regenerative cytokines, including TGF-β and IL-10 3,4 .”
Contini, V. E., Queiroz, Z. A. D. J., Catanozi, S., Filho, A. D. S., da Silveira, L. K. R., Santos, A. S., Fernezlian, S., Frediani, D., Lobo, T. D. M., Almeida, J. A., et al. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms27010197 · Cited by 2
Collaborative functionality between three types of inflammation in idiopathic pulmonary fibrosis
Fabre, T., Wynn, T. A., & Hart, K. M. (2026) · Nature Immunology · doi:10.1038/s41590-026-02616-1 · Cited by 2
“72,73), consistent with fibrosis being associated with mixed type 2 and 3 inflammation 53,54,74 .”
Self-citationCausal effect of immune cells on idiopathic pulmonary fibrosis: A mendelian randomization study
Li, X., Zhou, B., Xu, F., Liu, H., & Jia, X. (2024) · Heart & Lung · doi:10.1016/j.hrtlng.2024.06.003 · Cited by 3
Gangi, S., Bergantini, L., Paggi, I., Spalletti, M., Cameli, P., Bargagli, E., & d’Alessandro, M. (2025) · Immunity Inflammation and Disease · doi:10.1002/iid3.70123 · Cited by 2
Effects of immunosuppressive agents on T h17 cells involved in transplantation
Wang, X., van Velkinburgh, J. C., Zhang, Y., Ni, B., & Yang, Z. (2012) · Clinical Transplantation · doi:10.1111/ctr.12043 · Cited by 2
A comparative analysis of the molecular basis of fibrosis between tissues
Miller, R., Fell, M. J., & Pleat, J. (2017) · Comparative Clinical Pathology · doi:10.1007/s00580-017-2400-z · Cited by 2
“Supporting this, both IL-17A and IL-1β are increased in the lungs of idiopathic pulmonary fibrosis patients (Wilson et al. 2010).”
InfluentialCOPD and Other Inflammatory Diseases of the Lung: Focus on AhR Signaling
Beamer, C. A., Seaver, B. P., & Shepherd, D. M. (2012) · Molecular and integrative toxicology · doi:10.1007/978-1-61779-812-2_13 · Cited by 2
Role of DAMPs in Tissue Regeneration and Repair
Land, W. G. (2018) · Springer eBooks · doi:10.1007/978-3-319-78655-1_36 · Cited by 2
Ruwanpura, S. M., Rosli, S., & Tate, M. D. (2018) · Experientia supplementum · doi:10.1007/978-3-319-89390-7_4 · Cited by 2
Matson, S. M., Lee, J. S., & Fontenot, A. P. (2023) · Elsevier eBooks · doi:10.1016/b978-0-7020-8165-1.00072-1 · Cited by 2
Metwali, N., Stapleton, E. M., Hađina, S., & Thorne, P. S. (2024) · Physiological Reports · doi:10.14814/phy2.16115 · Cited by 2
“Pustulan also significantly increased IL-17 concentrations in the airspace (Figure 3) which is thought to play a direct role in lung fibrosis (Wilson et al., 2010; Zhang et al., 2019).”
BackgroundBoin, F., & Chizzolini, C. (2011) · Springer eBooks · doi:10.1007/978-1-4419-5774-0_15 · Cited by 2
Hirkane, P. S., Verma, U. P., Verma, A. K., & Singh, P. (2024) · Cureus · doi:10.7759/cureus.53157 · Cited by 1
“Wilson MS et al. in 2010 discussed the role of IL-1 β and IL-17 in IPF and came to the conclusion that individuals with IPF had higher IL-1 β levels in their BALF [19].”
ResultLee, K. H., Woo, J. S., Jeong, H. Y., Choi, J. W., Bang, C. H., Youn, J., Park, S., & Cho, M. (2024) · Immune Network · doi:10.4110/in.2024.24.e37 · Cited by 2
Hu, L., Liu, R., Han, S., Zhang, R., Zhou, Y., & Cao, Y. (2025) · Gene · doi:10.1016/j.gene.2025.149717 · Cited by 1
The role of IL-17 family in the process of pulmonary fibrosis
Zhou, G., Li, A., & Wang, R. (2025) · Life Conflux · doi:10.71321/tg620c27 · Cited by 1
“Multiple studies have shown that BLM stimulation triggers neutrophil infiltration through the IL-17-dependent pathway, significantly increasing IL-6 and IL-1 β levels, ultimately promoting abnormal collagen deposition [18].”
Alam, J., Yap, Y. A., Ang, C., Xie, L., Shane, H. L., Mackay, C. R., & Robert, R. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1728419 · Cited by 1
Harnessing the lung microbiome for precision management of fibrotic lung disease
Leroy, S., Roméo, B., Belaïd, A., Brest, P., Marquette, C., Vouret‐Craviari, V., Hofman, V., Hofman, P. M., & Mograbi, B. (2026) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2026.02.002 · Cited by 3
Oláh, P., Celec, P., Vlková, B., & Rejleková, K. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1861834 · Cited by 1
Wang, C., Zhu, B., Chen, M., Chen, G., Xu, M., & Pan, R. (2019) · Experimental and Therapeutic Medicine · doi:10.3892/etm.2019.7257 · Cited by 1
“Importantly, IL‐17A has been reported to exhibit a vital role in the development of pulmonary fibrosis, suggesting it is a potential treatment target for inflammation-induced fibrosis (25).”
BackgroundLoeh, B., Korfei, M., Mahavadi, P., Wasnick, R. M., von der Beck, D., & Günther, A. (2016) · European Respiratory Society eBooks · doi:10.1183/2312508x.10004815 · Cited by 1
Zhang, Q., Wang, Y., Tian, C., Yu, J., Li, Y., & Yang, J. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.1050200 · Cited by 1
Jayabalan, M., Sankar, S., Govindan, M., Nagarathnam, R., & Ibrahim, M. (2023) · 3 Biotech · doi:10.1007/s13205-023-03815-5 · Cited by 1
“On the other hand, cytokines like IL-1β determine the severity of fibrosis as it stimulates apoptosis of cardiomyocytes by combining with TNF-α (Ing et al. 1999; Wilson et al. 2010).”
BackgroundIL-22 Binding Protein/IL-22 Axis in Regulating Acute Lung Injury
Pillar, A. L., & Ali, M. K. (2024) · American Journal Of Pathology · doi:10.1016/j.ajpath.2024.01.002 · Cited by 1
Elsayed, N. (2025) · Results in Chemistry · doi:10.1016/j.rechem.2025.102472 · Cited by 1
Guo, L. (2018) · Annals of Oncology · doi:10.1093/annonc/mdy291.011 · Cited by 1
Role of the Adaptive Immune System in Angiotensin II Induced Vascular Remodeling and Stiffening
Tawinwung, S. (2013) · UA Campus Repository (The University of Arizona) · Cited by 1
Macrophages: the overlooked target for pulmonary fibrosis and COPD
Boorsma, C. E. (2016) · University of Groningen research database (University of Groningen / Centre for Information Technology) · Cited by 1
Lung Fibrosis Finds an Unsung Hero in Neuropeptide Y
Madala, S. K., & Reznikov, L. R. (2022) · American Journal of Respiratory Cell and Molecular Biology · doi:10.1165/rcmb.2022-0375ed · Cited by 1
“IL-1b is a well-studied proinflammatory cytokine that has been shown to be upregulated in several fibrotic lung diseases, including IPF, and is implicated to play a critical role in both wound repair and pulmonary fibrosis (2).”
BackgroundSelf-citationTargeting Inflammation to Control Tissue Fibrosis
Song, W., Sun, W., Wang, Z., Teo, K. Y. C., Cheung, C. M. G., & Wang, X. (2022) · International Journal of Drug Discovery and Pharmacology · doi:10.53941/ijddp.v1i1.206 · Cited by 1
Inflammation du tissu adipeux au cours de l'obésité humaine : implication des lymphocytes Th17
Caër, C. (2016) · theses.fr (ABES) · doi:10.70675/65eca5dczaa63z4e9az82dbzb223bfe8ef82 · Cited by 7
Interleukin-17 and T Helper 17 Cells in Mucosal Immunity of the Lung
Paats, M. S., van, P. T. W., Baan, C. C., Hoogsteden, H. C., van der Eerden, M. M., & Hendriks, R. W. (2012) · InTech eBooks · doi:10.5772/34300
“Furthermore, several studies have now linked IL-17 to fibrosis in the lung in mouse models of pulmonary fibrosis and idiopathic pulmonary fibrosis in humans (Braun et al. 2010; Kurasawa et al. 2000; Wilson et al. 2010).”
Immune Modulation of Vascular Stiffening
Majeed, B. A. (2014) · UA Campus Repository (The University of Arizona)
Zhou, T., Cui, X., Zhou, Y., Guo, J., Rong, Y., & Chen, W. (2015) · Environmental Toxicology and Pharmacology · doi:10.1016/j.etap.2014.12.017 · Cited by 1
Facco, M., Cabrelle, A., & Agostini, C. (2011) · Thorax · doi:10.1136/thx.2011.159558
“Finally, patients with idiopathic pulmonary fibrosis show high BAL levels of IL-17.(3) Concerning putative mechanism through which IL-17 could in theory regulate neutrophil activation and recruitment, we are evaluating whether pulmonary IL-17 favours granulopoiesis in DPLD (via granulocyte colony stimulating factor or…”
BackgroundInfluentialAbramovits, W., & Oquendo, M. (2013)
Potential Mechanistic Links Between Aging and IPF
Pan, H., Gulati, M., & Herzog, E. L. (2015) · WORLD SCIENTIFIC eBooks · doi:10.1142/9789814635011_0016
Environment and the Role of Inflammation in Chronic Pulmonary Diseases: The Silent Mediator
Yao, H., & Rahman, I. (2011) · Oxidative stress and disease · doi:10.1201/b11014-4
Thérapie ciblée anti-OX40 Ligand dans des modèles murins de Sclérodermie systémique
Elhaï, M. (2015) · theses.fr (ABES) · doi:10.70675/43e178dbzd310z46dczb297z9d026198fb4b
Basic Mechanisms Linking Inflammation and Fibrosis
Chizzolini, C. (2017) · Rare diseases of the immune system · doi:10.1007/978-3-319-41349-5_2
T Helper Cells in the Immunopathogenesis of Systemic Sclerosis – Current Trends
Krasimirova, E., & Kyurkchiev, D. S. (2017) · Acta Medica Bulgarica · doi:10.1515/amb-2017-0010
“More recently, another research group reported that bleomycin- and IL-1β – mediated pulmonary fi brosis is highly dependent on IL-17A and simultaneously requires transforming growth factor-beta (TGF-β) in mouse models [14].”
BackgroundBone marrow mesenchymal stem cells inhibited bleomycin-induced lung fibrosis
Nan, J., & Zhao, Z. (2017) · RSC Advances · doi:10.1039/c7ra03971a
Lee, J. S., & Fontenot, A. P. (2019) · Elsevier eBooks · doi:10.1016/b978-0-7020-6896-6.00072-7
Blandinières, A. (2018) · theses.fr (ABES) · doi:10.70675/9178d6fcz7e4ez48deza1dcz0840f8c96b22
Pathogenesis of Fibrosis—The Lung as a Model
Jefferies, C. A. (2019) · Elsevier eBooks · doi:10.1016/b978-0-323-47927-1.00019-0
The Role of Ninjurin1 on Pulmonary Fibrosis
Choi, S. H. (2019)
Fontenot, A. P., & Simonian, P. L. (2013) · Elsevier eBooks · doi:10.1016/b978-0-7234-3691-1.00085-4
Challenges in Approaching Management of Pulmonary Fibrosis
Al-Hayfani, M., Kawy, H. S. A., & Kamel, F. O. (2020) · Journal of Pharmaceutical Research International · doi:10.9734/jpri/2020/v32i2330788
Is Immune Response Relevant in Interstitial Lung Disease?
Khan, M. M. (2020) · Current Immunology Reviews · doi:10.2174/1573395516999200914143054
Abebayehu, D., Yeh, C., Bingham, G. C., Ewald, S. E., & Barker, T. H. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.05.11.443647
“mechanism of this biology is unclear [16].”
Song, Z., & Lin, Y.-M. (2021) · E3S Web of Conferences · doi:10.1051/e3sconf/202126702026 · Cited by 1
Doherty, M. T. (2011) · Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature · doi:10.3410/f.13334996.14748072
The Role of the Interleukin 1 Family in Lung Disease
Reilly, W. J., Burgoyne, R. A., & Borthwick, L. A. (2021) · Elsevier eBooks · doi:10.1016/b978-0-08-102723-3.00165-7
Adaptive Immunity in Interstitial Lung Disease
Winkler, J., & Herzog, E. L. (2021) · Elsevier eBooks · doi:10.1016/b978-0-08-102723-3.00018-4
Liu, G., Gong, L., Zhu, H., Li, C., Li, P., Liu, C., Tang, H., Wu, K., Wu, J., & Liu, D. (2020) · doi:10.21203/rs.3.rs-16427/v1
“Previous studies have indicated that multiple cytokines, including TGF-β1, IL1β, TNF-α, IL-17, IL-27, IL-13, and IL-32, are overexpressed in pulmonary fibrosis [29-32].”
BackgroundDynamics of regulatory T cells in lung transplant patients
de Silva, A. T. A. (2022) · Queensland University of Technology · doi:10.5204/thesis.eprints.230504
Pulmonary Fibrosis: One Manifestation, Various Diseases
Ruaro, B., Matucci‐Cerinic, M., Baratella, E., Confalonieri, M., Salton, F., & Hughes, M. (2022) · Frontiers research topics · doi:10.3389/978-2-83250-654-7
Activation of the P2RX7/IL-18 pathway in immune cells attenuates lung fibrosisPreprint
Hreich, S. J. D., Juhel, T., Leroy, S., Ghinet, A., Brau, F., Hofman, V., Hofman, P. M., & Vouret‐Craviari, V. (2023) · eLife · doi:10.7554/elife.88138.1
Author Response: Activation of the P2RX7/IL-18 pathway in immune cells attenuates lung fibrosis
Hreich, S. J. D., Juhel, T., Leroy, S., Ghinet, A., Brau, F., Hofman, V., Hofman, P. M., & Vouret‐Craviari, V. (2024) · eLife · doi:10.7554/elife.88138.4.sa3
Rôle de l'immunomodulateur P2RX7 dans le cancer et la fibrose pulmonaire
Hreich, S. J. D. (2022) · theses.fr (ABES) · doi:10.70675/4b399e7fzb436z4e8fz8045z90c0862c799d
Adoptive transfer of CD49a + Tissue resident memory cells reverses pulmonary fibrosis in micePreprint
Collins, S. L., Chan‐Li, Y., Shenderov, K., Gillich, A., Nelson, A. M., Loube, J., Mitzner, W., Powell, J. D., & Horton, M. R. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.03.13.584814
Zhang, R., Chen, S., Chen, L., Ye, L., Jiang, Y., Peng, H., Guo, Z., Li, M., Jiang, X., Guo, P., et al. (2022) · Figshare · doi:10.6084/m9.figshare.20154326
Zhang, R., Chen, S., Chen, L., Ye, L., Jiang, Y., Peng, H., Guo, Z., Li, M., Jiang, X., Guo, P., et al. (2022) · Figshare · doi:10.6084/m9.figshare.20154320
Zhang, R., Chen, S., Chen, L., Ye, L., Jiang, Y., Peng, H., Guo, Z., Li, M., Jiang, X., Guo, P., et al. (2022) · Figshare · doi:10.6084/m9.figshare.20154323
Luo, H., Yan, J., & Zhou, X. (2023) · Figshare · doi:10.6084/m9.figshare.24406688
Zhang, R., Chen, S., Chen, L., Ye, L., Jiang, Y., Peng, H., Guo, Z., Li, M., Jiang, X., Guo, P., et al. (2022) · Figshare · doi:10.6084/m9.figshare.20154329
Inflammation and Immunity in Systemic Sclerosis
Boin, F., Gabrielli, A., & Chizzolini, C. (2024) · Springer eBooks · doi:10.1007/978-3-031-40658-4_14
Reply to Ward et al. : Integrating Aerodigestive Investigations in Progressive Pulmonary Fibrosis
O’Dwyer, D. N., Kim, J. S., & Noth, I. (2024) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.202406-1123le
“…aspiration is common even in health, aspirated quantities are suf fi cient to contain physiologically active bacteria, and an increasing similarity between oral and lung microbiota is associated with Th17 lung immunity (a cytokine system that can also associate with fi brogenesis) (9 – 11).”
BackgroundFollicular helper T cells and fibrotic diseases
Ma, Y., Zhou, Y., & Yu, M. (2025) · Cellular Immunology · doi:10.1016/j.cellimm.2025.105024
Regulation of Type II Responses in Lung Fibrosis and Systemic Autoimmunity: A Dissertation
Brodeur, T. Y. (2014) · The Journal of the American Medical Association (JAMA) Network (American Medical Association) · doi:10.13028/m2mp44
“IFN-γ (Fielding et al., 2014), IL-13 (Wynn, 2011), and IL-17A (Oh et al., 2011; Wilson et al., 2010) have all been associated with fibrosis, and the role T cell mediated cytotoxicity in this context remains unclear.”
BackgroundInfluentialLiu, Q., Bi, Y., Song, S., Zhu, K., Qiao, X., Wang, H., & Ji, G. (2024) · Figshare · doi:10.6084/m9.figshare.26615017
Zhang, R., Chen, S., Chen, L., Ye, L., Jiang, Y., Peng, H., Guo, Z., Li, M., Jiang, X., Guo, P., et al. (2022) · Figshare · doi:10.6084/m9.figshare.20154332
Liu, Q., Bi, Y., Song, S., Zhu, K., Qiao, X., Wang, H., & Ji, G. (2024) · Figshare · doi:10.6084/m9.figshare.26615035
Liu, Q., Bi, Y., Song, S., Zhu, K., Qiao, X., Wang, H., & Ji, G. (2024) · Figshare · doi:10.6084/m9.figshare.26615038
Liu, Q., Bi, Y., Song, S., Zhu, K., Qiao, X., Wang, H., & Ji, G. (2024) · Figshare · doi:10.6084/m9.figshare.26615029
Liu, Q., Bi, Y., Song, S., Zhu, K., Qiao, X., Wang, H., & Ji, G. (2024) · Figshare · doi:10.6084/m9.figshare.26615032
Liu, Q., Bi, Y., Song, S., Zhu, K., Qiao, X., Wang, H., & Ji, G. (2024) · Figshare · doi:10.6084/m9.figshare.26615014
Liu, Q., Bi, Y., Song, S., Zhu, K., Qiao, X., Wang, H., & Ji, G. (2024) · Figshare · doi:10.6084/m9.figshare.26615023
Metadata
- Authors
- Wilson, M. S., Madala, S. K., Ramalingam, T. R., Gochuico, B. R., Rosas, I. O., Cheever, A. W., & Wynn, T. A.
- Affiliations
- National Institutes of Health (US)
- Brigham and Women’s Hospital, Harvard Medical School, Boston, MA 02115 3
- Biomedical Research Institute (US)
- Corresponding author
- Wynn, Thomas A.
- ORCID
- Venue
- Journal of Experimental Medicine
- Publisher
- Rockefeller University Press
- Published
- 2010-02-22
- Volume
- 207
- Issue
- 3
- Pages
- 535-552
- ISSN
- 0022-1007 (ISSN-L)
- 1540-9538
- PMC
- PMC2839145
- OpenAlex
- W2095715691
- Cited by
- 730
- References
- 84
- Citations by year
- 2026: 28 · 2025: 39 · 2024: 68 · 2023: 45 · 2022: 47 · 2021: 39 · 2020: 38 · 2019: 51 · 2018: 47 · 2017: 48 · 2016: 42 · 2015: 42 · 2014: 40 · 2013: 57 · 2012: 45
- FWCI
- 41.61
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- cc-by-nc-sa
- Locations
- The Journal of Experimental Medicine (publishedVersion)
- PubMed Central (publishedVersion, cc-by-nc-sa)
- PubMed (publishedVersion)
- Digital Access to Scholarship at Harvard (DASH) (Harvard University) (submittedVersion, cc-by)
- Funders
- National Institutes of Health
- Topics
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
- Health Sciences › Medicine › Surgery › Transplantation: Methods and Outcomes
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Pulmonary Hypertension Research and Treatments
- Keywords
- idiopathic pulmonary fibrosis, IL-17A, bleomycin-induced lung injury, IL-1β, pulmonary fibrosis, TGF-beta, IL-10, interferon-gamma, IL-12/23p40, γδ T cells, CD4+ T cells, neutrophilia, Schistosoma mansoni eggs, bronchoalveolar lavage, IL-17A blockade
- MeSH terms
- Animals, Bleomycin, Interferon-gamma, Lung, Male, Mice, Inbred C57BL, Pulmonary Fibrosis, Schistosoma mansoni, Schistosomiasis mansoni, CD4-Positive T-Lymphocytes, Interleukin-10, Mice, Knockout, Interleukin-13, Interleukin-17, Mice, Interleukin-1beta, Interleukin-12 Subunit p40
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.